149 related articles for article (PubMed ID: 29677628)
1. Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.
Rodríguez-Gallego E; Gómez J; Domingo P; Ferrando-Martínez S; Peraire J; Viladés C; Veloso S; López-Dupla M; Beltrán-Debón R; Alba V; Vargas M; Castellano AJ; Leal M; Pacheco YM; Ruiz-Mateos E; Gutiérrez F; Vidal F; Rull A;
Atherosclerosis; 2018 Jun; 273():28-36. PubMed ID: 29677628
[TBL] [Abstract][Full Text] [Related]
2. A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients.
Rodríguez-Gallego E; Gómez J; Pacheco YM; Peraire J; Viladés C; Beltrán-Debón R; Mallol R; López-Dupla M; Veloso S; Alba V; Blanco J; Cañellas N; Rull A; Leal M; Correig X; Domingo P; Vidal F
AIDS; 2018 Mar; 32(5):565-573. PubMed ID: 29280761
[TBL] [Abstract][Full Text] [Related]
3. The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI.
Liu S; Wei B; Liang W; Chen T; Deng L; Zhao M; Wan J
Front Public Health; 2023; 11():1161503. PubMed ID: 37181701
[TBL] [Abstract][Full Text] [Related]
4. Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients.
Dave JA; Levitt NS; Ross IL; Lacerda M; Maartens G; Blom D
PLoS One; 2016; 11(3):e0151911. PubMed ID: 26986065
[TBL] [Abstract][Full Text] [Related]
5. Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.
Estrada V; Geijo P; Fuentes-Ferrer M; Alcalde ML; Rodrigo M; Galindo MJ; Muñoz A; Domingo P; Ribera E; Cosín J; Viciana P; Lozano F; Terrón A; Vergara A; Teira R; Muñoz-Sánchez J; Roca B; Sánchez T; López-Aldeguer J; Deig E; Vidal F; Pedrol E; Castaño-Carracedo M; Puig T; Garrido M; Suárez-Lozano I
BMC Womens Health; 2011 Aug; 11():36. PubMed ID: 21816091
[TBL] [Abstract][Full Text] [Related]
6. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.
Padmapriyadarsini C; Ramesh Kumar S; Terrin N; Narendran G; Menon PA; Ramachandran G; Subramanyan S; Venkatesan P; Wanke C; Swaminathan S
Clin Infect Dis; 2011 Feb; 52(4):540-6. PubMed ID: 21252141
[TBL] [Abstract][Full Text] [Related]
7. Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis.
Nduka C; Sarki A; Uthman O; Stranges S
Int J Cardiol; 2015 Nov; 199():307-18. PubMed ID: 26241636
[TBL] [Abstract][Full Text] [Related]
8. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
[TBL] [Abstract][Full Text] [Related]
9. Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.
Lampe FC; Duprez DA; Kuller LH; Tracy R; Otvos J; Stroes E; Cooper DA; Hoy J; Paton NI; Friis-Møller N; Neuhaus J; Liappis AP; Phillips AN;
J Acquir Immune Defic Syndr; 2010 Jul; 54(3):275-84. PubMed ID: 20658749
[TBL] [Abstract][Full Text] [Related]
10. Lipids profile among ART-naïve HIV infected patients and men who have sex with men in China: a case control study.
Wang Q; Ding H; Xu J; Geng W; Liu J; Guo X; Kang J; Li X; Jiang Y; Shang H
Lipids Health Dis; 2016 Sep; 15(1):149. PubMed ID: 27600391
[TBL] [Abstract][Full Text] [Related]
11. Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients in a Ghanaian population: A case-control study.
Obirikorang C; Acheampong E; Quaye L; Yorke J; Amos-Abanyie EK; Akyaw PA; Anto EO; Bani SB; Asamoah EA; Batu EN
PLoS One; 2020; 15(1):e0227779. PubMed ID: 31929604
[TBL] [Abstract][Full Text] [Related]
12. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
Rotger M; Bayard C; Taffé P; Martinez R; Cavassini M; Bernasconi E; Battegay M; Hirschel B; Furrer H; Witteck A; Weber R; Ledergerber B; Telenti A; Tarr PE;
Circ Cardiovasc Genet; 2009 Dec; 2(6):621-8. PubMed ID: 20031643
[TBL] [Abstract][Full Text] [Related]
13. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Pennell P; Leclercq B; Delahunty MI; Walters BA
Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
[TBL] [Abstract][Full Text] [Related]
14. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
[TBL] [Abstract][Full Text] [Related]
15. Association of adiponectin/leptin ratio with carbohydrate and lipid metabolism parameters in HIV-infected patients during antiretroviral therapy.
Tiliscan C; Arama V; Mihailescu R; Munteanu D; Iacob DG; Popescu C; Catana R; Negru A; Lobodan A; Arama SS
Endocr Res; 2018 Aug; 43(3):149-154. PubMed ID: 29451987
[TBL] [Abstract][Full Text] [Related]
16. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
[TBL] [Abstract][Full Text] [Related]
17. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.
Liu E; Armstrong C; Spiegelman D; Chalamilla G; Njelekela M; Hawkins C; Hertzmark E; Li N; Aris E; Muhihi A; Semu H; Fawzi W
Clin Infect Dis; 2013 Jun; 56(12):1820-8. PubMed ID: 23449270
[TBL] [Abstract][Full Text] [Related]
18. Early increases in concentrations of total, LDL, and HDL cholesterol in HIV-infected children following new exposure to antiretroviral therapy.
Sztam KA; Jiang H; Jurgrau A; Deckelbaum RJ; Foca MD
J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):495-8. PubMed ID: 21206378
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism.
Aragonès G; Alonso-Villaverde C; Pardo-Reche P; Rull A; Beltrán-Debón R; Rodríguez-Gallego E; Fernández-Sender L; Camps J; Joven J
BMC Med Genet; 2011 Sep; 12():120. PubMed ID: 21939545
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
